Mechanisms underlying methotrexate-induced pulmonary toxicity

Expert Opinion on Drug Safety

Volumn 8, Issue 4, 2009, Pages 451-458

  Kim, Youn Jung ^a   Song, Mee ^a   Ryu, Jae Chun ^a  

^a Korea Institute of Science and Technology   (South Korea)

Author keywords

Mechanism; Methotrexate; p38 MAPK; Pulmonary toxicity

Indexed keywords

CYTOKINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC INFLAMMATION; COUGHING; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG WITHDRAWAL; DYSPNEA; ENZYME ACTIVATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTERSTITIAL PNEUMONIA; LOW DRUG DOSE; LUNG FIBROSIS; LUNG GRANULOMA; LUNG TOXICITY; LYMPHOCYTIC INFILTRATION; NEOPLASM; PHARMACOGENOMICS; PNEUMONIA; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ARTHRITIS, RHEUMATOID; ENZYME ACTIVATION; GENOTYPE; HUMANS; LUNG DISEASES; METABOLIC DETOXICATION, DRUG; METHOTREXATE; MODELS, BIOLOGICAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 67650511052     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903066734     Document Type: Review

References (72)

1. Rosenow EC. Drug-induced pulmonary disease. Dis Mon 1994;40:253-310
2. Genestier L, Paillot R, Quemeneur L, et al. Mechanisms of action of methotrexate. Immunopharmacology 2000;47(2-3):247-257
3. Linnebank M, Moskau S, Jürgens A, et al. Association of genetic variants of methionine matabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma.Neuro Oncol 2009;11:2-8
4. Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006;58:473-492
5. Weisman MH, Furst DE, Park GS, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006;54:607-12 • Clinical study of methotrexate-related side effects.
6. StClair EW, van der Heijide DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43 • Clinical study of methotrexate-related side effects.
7. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40:1829-37 • Clinical study of methotrexate-related side effects.
8. Yamauchi Y, Okazaki H, Desaki M., et al. Methotrexate induces interleukin-8 production by human bronchial and alveolar epithelial cells. Clin Sci 2004;106:619-625 (Pubitemid 38797575)
9. Hsu PC, Lan JL, Hsieh TY, et al. Methotrexate pneumonitis in a patient with rheumatoid arthritis. J Microbiol Immunol Infect 2003;36:137-140 (Pubitemid 36857076)
10. Chikura B, Sathi N, Lane S, et al. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology 2008;47(11):1647-50 • Clinical study of methotrexate-related side effects.
11. Thavarajah K, Wu P, Rhew EJ, et al. Pulmonary complications of tumor necrosis factor-targeted therapy. Respir Med 2009;103(5):661-669
12. Mornex JF, Cordier G, Pages J, et al. Activated lung lymphocytes in hypersensitivity pneumonitis. J Allergy Clin Immunol 1984;74(5):719-727 (Pubitemid 15210998)
13. Akoun GM, Gauthier-Rahman S, Mayaud CM, et al. Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologic cell-mediated mechanism. Chest 1987;91(1):96-99
14. Schnabel A, Richter C, Bauerfeind S, et al. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997;52(4):377-379 (Pubitemid 27204903)
15. Enelow RI, Mohammed AZ, Stoler MH, et al. Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease. J Clin Invest 1998;102(9):1653-1661 (Pubitemid 28516250)
16. Fujimori Y, Kataoka M, Tada S, et al. The role of Interleukin-8 in interstitial pneumonia. Respirology 2003;8:33-40
17. Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341(17):1264-1269 (Pubitemid 29489741)
18. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134(2):136-151 (Pubitemid 32096342)
19. Obavashi Y, Yamadori I, Fujita J, et al. The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis. Chest 1997;112(5):1338-1343 (Pubitemid 27497869)
20. Crestani B, Dehoux M, Hayem G, et al. Differential role of neutrophils and alveolar macrophages in hepatocyte growth factor production in pulmonary fibrosis. Lab Invest 2002;82(8):1015-1022 (Pubitemid 34894350)
21. Pardo A, Barrios R, Gaxiola M, et al. Increase of lung neutrophils in hypersensitivity pneumonitis is associated with lung fibrosis. Am J Respir Crit Care Med 2000;161(5):1698-1704 (Pubitemid 30329050)
22. Lin YH, Haslam PL, Turner-Warwick M. Chronic pulmonary sarcoidosis: relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests. Thorax 1985;40(7):501-507 (Pubitemid 15026218)
23. Robbins RA, Jinkins PA, Bryan TW, et al. Methotrexate inhibition of inducible nitric oxide synthase in murine lung epithelial cells in vitro. Am J Respir Cell Mol Biol 1998;18(6):853-859 (Pubitemid 128358432)
24. Daba MH, El-Tahir KE, Al-Arifi MN, et al. Drug-induced pulmonary fibrosis. Saudi Med J 2004;25(6):700-706
25. Schnabel A, Reinhold-Keller E, Willmann V, et al. Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. Rheumatol Int 1994;14(1):33-38 (Pubitemid 24189748)
26. van Ede AE, Laan RF, Blom HJ, et al. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998;27(5):277-292 (Pubitemid 28176234)
27. Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 1994;20(2):513-528 (Pubitemid 24163463)
28. Grosflam J, Weinblatt ME. Methotrexate: mechanism of action, pharmacokinetics, clinical indications, and toxicity. Curr Opin Rheumatol 1991;3(3):363-368
29. Kremer JM. Methotrexate update. Scand J Rheumatol 1996;25(6):341-344
30. Hirata S, Matsubara T, Saura R, et al. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989;32(9):1065-1073 (Pubitemid 19237859)
31. Merkle CJ, Moore IM, Penton BS, et al. Methotrexate causes apoptosis in postmitotic endothelial cells. Biol Res Nurs 2000;2(1):5-14
32. Olsen NJ, Murray LM. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989;32(4):378-385 (Pubitemid 19118662)
33. Olsen NJ, Callahan LF, Pincus T. Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheu 1987;30(5):481-488 (Pubitemid 17108100)
34. Nesher G, Moore TL. The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum 1990;33(7):954-959
35. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92(6):2675-2682 (Pubitemid 24006532)
36. Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 2003;138:501-511 (Pubitemid 36269490)
37. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996;39(12):1951-1960
38. H Wolf RE, Granger DN. Leukocyte adherence in rat mesenteric venules: effects of adenosine and methotrexate. Gastroenterology 1993;104(1):31-37 (Pubitemid 23040003)
39. Cronstein BN, Levin RI, Belanoff J, et al. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986;78(3):760-770 (Pubitemid 16024813)
40. Cronstein BN, Rosenstein ED, Kramer SB, et al. Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J Immunol 1985;135(2):1366-1371 (Pubitemid 16237462)
41. Parmely MJ, Zhou WW, Edwards CK, et al. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 1993;151(1):389-396 (Pubitemid 23207004)
42. Lappin D, Whaley K. Adenosine A2 receptors on human monocytes modulate C2 production. Clin Exp Immunol 1984;57(2):454-460 (Pubitemid 14089396)
43. Ranganathan P, Eisen S, Yokoyama WM, et al. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 2003;62(1):4-9 • Summary of methotrexate toxicity in pharmacogenetics aspects.
44. Banerjee D, Mayer-Kuckuk P, Capiaux G, et al. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002;1587(2-3):164-173 (Pubitemid 34657277)
45. Stamp L, Roberts R, Kennedy M, et al. The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed Pharmacother 2006;60(10):678-687
46. de Graaf D, Sharma RC, Mechetner EB, et al. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci USA 1996;93:1238-1242 (Pubitemid 26052872)
47. Yoshida S, Onuma K, Amayasu H, et al. Elevated levels of IL-8 in interstitial pneumonia induced by low-dose methotrexate. J Allergy Clin Immunol 1999;103:952-954 (Pubitemid 29297604)
48. Yoshimura T, Matsushima K, Oppenheim JJ, et al. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin-1 (IL1). J Immunol 1987; 39:788-793 (Pubitemid 17107077)
49. Standiford TJ, Kunkel SL, Basha MA, et al. Interleukin-8 gene expression by a pulmonary epithelial cell line. A model for cytokine networks in the lung. J Clin Invest 1999;86:1945-1953
50. Nakagami H, Pitzschke A, Hirt H. Emerging MAP kinase pathways in plant stress signalling. Trends Plant Sci 2005;10(7):339-346 (Pubitemid 40912457)
51. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912
52. Ge B, Xiong X, Jing Q, et al. TAB1beta (transforming growth factor-beta-activated protein kinase 1-binding protein 1beta), a novel splicing variant of TAB1 that interacts with p38alpha but not TAK1. J Biol Chem 2003;278:2286-2293 (Pubitemid 36801298)
53. Kim YJ, Song M, Ryu JC. Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology 2009;256(3):183-90 •• Recent study of the mechanism of methotrexate-induced pulmonary toxicity in gene levels. So far, the accurate mechanism of methotrexate-induced pulmonary toxicity is not found.
54. Holtmann H, Enninga J, Kalble S, et al. The MAPK kinase kinase TAK1 plays a central role in coupling the interleukin-1 receptor to both transcriptional and RNA-targeted mechanisms of gene regulation. J Biol Chem 2001;276:3508-3516 (Pubitemid 37411650)
55. Choo MK, Sakurai H, Koizumi K, et al. TAK1-mediated stress signaling pathways are essential for TNF-alpha-promoted pulmonary metastasis of murine colon cancer cells. Int J Cancer 2006;118:2758-2764 (Pubitemid 43673354)
56. Alford KA, Glennie S, Turrell BR, et al. Heat shock protein 27 functions in inflammatory gene expression and transforming growth factor-beta-activated kinase-1 (TAK1)-mediated signaling. J Biol Chem 2007;282:6232-6241 (Pubitemid 47100877)
57. Kim AL, Labasi JM, Zhu Y, et al. Role of p38 MAPK in UVB-induced inflammatory responses in the skin of SKH-1 hairless mice. J Invest Dermatol 2005;124:1318-1325 (Pubitemid 40847422)
58. Ridley SH, Sarsfield SJ, Lee JC, et al. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol 1997;158(7):3165-3173 (Pubitemid 127484030)
59. Yang J, Hooper WC, Phillips DJ, et al. Regulation of proinflammatory cytokines in human lung epithelial cells infected with Mycoplasma pneumoniae. Infect Immun 2002;70:3649-3655 (Pubitemid 34666003)
60. Auron PE, Warner SJ, Webb AC, et al. Studies on the molecular nature of human interleukin 1. J Immunol 1987;138:1447-1456 (Pubitemid 17029439)
61. Nagaoka I, Trapnell BC, Crystal RG. Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophage of individuals with idiopathic pulmonary fibrosis. J Clin Invest 1990;85:2023-2027 (Pubitemid 20192983)
62. Broekelmann TJ, Limper AH, Colby TV, et al. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991;88:6642-6646 (Pubitemid 21915005)
63. Nagai S, Aung H, Takeuchi M, et al. IL-1 and IL-1 inhibitory activity in the culture supernatants of alveolar macrophages from patients with interstitial lung diseases. Chest 1991;99:674-680
64. Lynch JP, Standiford TJ, Rolphe MW, et al. Neutrophilic alveolitis in idiopathic pulmonary fibrosis. The role of interleukin-8. Am Rev Respir Dis 1992;145:1433-1439
65. Zhang Y, Lee TC, Guillemin B, et al. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol 1993;150:4188-4196 (Pubitemid 23129800)
66. Iyonaga K, Takeya M, Saita N, et al. Monocyte chemoattractant protein-1 in idiopathic pulmonary fibrosis and other interstitial lung diseases. Hum Pathol 1994;25:455-463 (Pubitemid 24173862)
67. Gerards AH, Lathouder S, Groot ER, et al. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 2003;42:1189-1196
68. Sarma NS, Kim YJ, Ryu JC. Differential gene expression profiling in human promyelocytic leukemia cells treated with benzene and ethylbenzene. Mol Cell Toxicol 2008;4(4):267-277
69. Kim YJ, Song MK, Sarma NS, et al. Functional gene analysis to identify potential markers induced by benzene in two different cell lines, HepG2 and HL-60. Mol Cell Toxicol 2008;4(3):183-191
70. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25(1):25-29 (Pubitemid 30257031)
71. Kushida T, Takagi T, Fukuda KI. Event ontology: a pathway-centric ontology for biological processes. Pac Symp Biocomput 2006;152-163
72. Te Pas MF, Hulsegge I, Coster A, et al. Biochemical pathways analysis of microarray results: regulation of myogenesis in pigs. BMC Dev Biol 2007;7:66 (Pubitemid 47062936)